Haleon (MEX:HLNN) Research & Development: MXN7,838 Mil (TTM As of Dec. 2025)


MEX:HLNN Haleon PLC MEX:HLNN
74 GF Score
Price MXN99.17
GF Value MXN107.88
! 3 Warning Signs
View Full Analysis

What is Haleon Research & Development?

Haleon MEX:HLNN 74 Research & Development is MXN7,838 Mil as of Dec. 2025. GuruFocus rates MEX:HLNN with a GF Score™ of 74/100 and a GF Value™ of MXN107.88. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Haleon's Research & Development for the six months ended in Dec. 2025 was MXN3,929 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was MXN7,838 Mil.

Haleon  (MEX:HLNN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Haleon Research & Development Related Terms

Haleon Research & Development Historical Data

* Premium members only.

The historical data trend for Haleon's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haleon Research & Development Chart

Haleon Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 7,010.77 7,124.00 6,682.27 7,857.14 7,616.87

Haleon Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,631.20 3,356.36 4,060.40 3,908.91 3,928.96
MEX:HLNN
74GF Score
Haleon PLC MEX:HLNN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haleon Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MXN7,838 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN7,838 Mil mean?
Haleon (MEX:HLNN) has a Research & Development of MXN7,838 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Haleon and its competitors.
Is Haleon's Research & Development too high?
Haleon's current Research & Development is MXN7,838 Mil. Overall, Haleon has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Haleon's Research & Development compare to ZTS and UTHR?
Haleon's Research & Development of MXN7,838 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Haleon and its competitors. Haleon's current Research & Development is MXN7,838 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Haleon (MEX:HLNN) has a current Research & Development of MXN7,838 Mil. The stock's GF Value™ is MXN107.88, compared to a current price of MXN99.17 — trading 8.1% below its estimated fair value. The current Research & Development is MXN7,838 Mil. Haleon's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Haleon (MEX:HLNN), the current Research & Development is MXN7,838 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haleon (MEX:HLNN) Overvalued in 2026?

Based on GuruFocus' analysis, Haleon stock appears to be undervalued. The current stock price of MXN99.17 is trading 8.1% below its estimated GF Value™ of MXN107.88.

Key valuation signals for MEX:HLNN:

  • Research & Development: MXN7,838 Mil
  • GF Value™: MXN107.88 vs. price of MXN99.17 (8.1% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the MEX:HLNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haleon Business Description

Address The Heights, Building 5, First Floor, Weybridge, Surrey, GBR, KT13 0NY
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
74GF Score

Get the complete analysis for MEX:HLNN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN99.17
Price
MXN107.88
GF Value